MP
GOSS icon

Mangrove Partners’s Gossamer Bio GOSS Stock Holding History

Mangrove Partners’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,747
Closed -$95.3K – 505
2025
Q4 		$95.3K Buy
+30,747
New +$87.7K 0.01% 355

Other funds holding GOSS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Mangrove Partners's GOSS Position: Q1 2026 in Review

Mangrove Partners sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 30,747 shares — an estimated $95.3K sold.

Mangrove Partners first reported a position in GOSS in Q4 2025 and held it in 1 quarter. The position peaked at $95.3K in Q4 2025. 185 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Mangrove Partners reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • Mangrove Partners sold 30,747 Gossamer Bio shares in Q1 2026, an estimated $95.3K.
  • Mangrove Partners first reported a position in Gossamer Bio in Q4 2025 and held it in 1 quarter.
  • Mangrove Partners's Gossamer Bio position peaked at $95.3K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.